Tenderwize
Retour à la recherche

Pharmaceutical Products

Amgros I/S·København Ø, Denmark·DKK 1564M | EUR 209.2M·Deadline Sep 03, 2026 · 13 days left·Open·Supplies
High valueStructured notice only
Titre original de l'avis

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

80/100

Score d'opportunité

PromisingLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

80 / 100

Complexité

30 / 100

Facteurs de risque

The stated estimated quantities are indicative only. Actual demand may be lower or higher based on patient needs and tr...

The framework is non-exclusive and without purchase obligation. The buyer may purchase from other sources even if you w...

Submission deadline in 13 days

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • DKK 1564M estimated value
  • Supplies contract
  • 2 lots
  • Duration until Dec 2028
  • Supply of Daratumumab (ATC L01FC01) in two different formulations and strengths.
  • Lot 1: 1800 mg injection, estimated 610,073 units.
Afficher le résumé complet

This is an open tender (framework agreement) by Amgros I/S for the supply of pharmaceutical products (Daratumumab) to Danish public hospital pharmacies. The tender is divided into two separate lots, each representing a different product form/dosage. Award is based solely on price (100% weight). No minimum eligibility requirements are imposed. The total estimated framework value is DKK 1,564,000,000 (approx. EUR 208,873,981). The procurement is EU-funded and conducted under Directive 2014/24/EU. Submission is electronic via a portal, with a deadline of 2026-09-03. Important: no procurement documents were analyzed; all data comes from the structured notice and XML notice.

Risques

The stated estimated quantities are indicative only. Actual demand may be lower or higher based on patient needs and tr...

The framework is non-exclusive and without purchase obligation. The buyer may purchase from other sources even if you w...

Submission deadline in 13 days

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Open procedure for a framework agreement.
  • Variants are not allowed.

Administrative

  • Tenders must be submitted electronically via Amgros procurement portal.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

100% price – lowest price wins.100%

Lot 2

100% price – lowest price wins.100%

Acheteur

Localisation

København Ø, DNK

Profil acheteur

Ouvrir le profil

Identifiant

14479880

Activité

Health

Lots (2)

LOT-0001

Tender No. 1

Supply of Daratumumab injection 1800 mg, estimated 610,073 units. Framework agreement with no purchase obligation. Real consumption may vary significantly from estimates.

SuppliesFrameworkEU fundedElectronic submission

EUR 209.2M

Valeur estimée

Localisation

DK011, Denmark

Durée

Dec 2026 - Dec 2028

Catégorie

Pharmaceutical products

Critères d'attribution

Price

LOT-0002

Tender No. 2

Supply of Daratumumab infusion 20 mg/ml in two pack sizes (5 ml and 20 ml), combined estimated 712 units. Framework agreement with no purchase obligation. Real consumption may vary.

SuppliesFrameworkEU fundedElectronic submission

EUR 209.2M

Valeur estimée

Localisation

DK011, Denmark

Durée

Dec 2026 - Dec 2028

Catégorie

Pharmaceutical products

Critères d'attribution

Price

Détails de la procédure

Date de publication
09 Jul 2026
Langues
Danish, Swedish

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
477000-2026

Documents (1)

Appels d'offres similaires